133
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Circulating Exosomal microRNAs as Biomarkers of Colon Cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Exosomal microRNAs (miRNAs) have been attracting major interest as potential diagnostic biomarkers of cancer. The aim of this study was to characterize the miRNA profiles of serum exosomes and to identify those that are altered in colorectal cancer (CRC). To evaluate their use as diagnostic biomarkers, the relationship between specific exosomal miRNA levels and pathological changes of patients, including disease stage and tumor resection, was examined.

          Experimental Design

          Microarray analyses of miRNAs in exosome-enriched fractions of serum samples from 88 primary CRC patients and 11 healthy controls were performed. The expression levels of miRNAs in the culture medium of five colon cancer cell lines were also compared with those in the culture medium of a normal colon-derived cell line. The expression profiles of miRNAs that were differentially expressed between CRC and control sample sets were verified using 29 paired samples from post-tumor resection patients. The sensitivities of selected miRNAs as biomarkers of CRC were evaluated and compared with those of known tumor markers (CA19-9 and CEA) using a receiver operating characteristic analysis. The expression levels of selected miRNAs were also validated by quantitative real-time RT-PCR analyses of an independent set of 13 CRC patients.

          Results

          The serum exosomal levels of seven miRNAs (let-7a, miR-1229, miR-1246, miR-150, miR-21, miR-223, and miR-23a) were significantly higher in primary CRC patients, even those with early stage disease, than in healthy controls, and were significantly down-regulated after surgical resection of tumors. These miRNAs were also secreted at significantly higher levels by colon cancer cell lines than by a normal colon-derived cell line. The high sensitivities of the seven selected exosomal miRNAs were confirmed by a receiver operating characteristic analysis.

          Conclusion

          Exosomal miRNA signatures appear to mirror pathological changes of CRC patients and several miRNAs are promising biomarkers for non-invasive diagnosis of the disease.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer.

          MicroRNA (miRNA) opens up a new field for molecular diagnosis of cancer. However, the role of circulating miRNAs in plasma/serum in cancer diagnosis is not clear. The aim of this study was to investigate whether plasma miRNAs can be used as biomarkers for the early detection of colorectal carcinoma (CRC). We measured the levels of 12 miRNAs (miR-134, -146a, -17-3p, -181d, -191, -221, -222, -223, -25, -29a, -320a and -92a) in plasma samples from patients with advanced colorectal neoplasia (carcinomas and advanced adenomas) and healthy controls using real-time RT-PCR. We found that plasma miR-29a and miR-92a have significant diagnostic value for advanced neoplasia. MiR-29a yielded an AUC (the areas under the ROC curve) of 0.844 and miR-92a yielded an AUC of 0.838 in discriminating CRC from controls. More importantly, these 2 miRNAs also could discriminate advanced adenomas from controls and yielded an AUC of 0.769 for miR-29a and 0.749 for miR-92a. Combined ROC analyses using these 2 miRNAs revealed an elevated AUC of 0.883 with 83.0% sensitivity and 84.7% specificity in discriminating CRC, and AUC of 0.773 with 73.0% sensitivity and 79.7% specificity in discriminating advanced adenomas. Collectively, these data suggest that plasma miR-29a and miR-92a have strong potential as novel noninvasive biomarkers for early detection of CRC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            MicroRNAs accurately identify cancer tissue origin.

            MicroRNAs (miRNAs) belong to a class of noncoding, regulatory RNAs that is involved in oncogenesis and shows remarkable tissue specificity. Their potential for tumor classification suggests they may be used in identifying the tissue in which cancers of unknown primary origin arose, a major clinical problem. We measured miRNA expression levels in 400 paraffin-embedded and fresh-frozen samples from 22 different tumor tissues and metastases. We used miRNA microarray data of 253 samples to construct a transparent classifier based on 48 miRNAs. Two-thirds of samples were classified with high confidence, with accuracy >90%. In an independent blinded test-set of 83 samples, overall high-confidence accuracy reached 89%. Classification accuracy reached 100% for most tissue classes, including 131 metastatic samples. We further validated the utility of the miRNA biomarkers by quantitative RT-PCR using 65 additional blinded test samples. Our findings demonstrate the effectiveness of miRNAs as biomarkers for tracing the tissue of origin of cancers of unknown primary origin.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Global cancer statistics

                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2014
                4 April 2014
                : 9
                : 4
                : e92921
                Affiliations
                [1 ]Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
                [2 ]Division of Cancer Development System, National Cancer Center Research Institute, Tokyo, Japan
                [3 ]Department of Gastroenterology, The University of Tokyo Hospital, Tokyo, Japan
                [4 ]Laboratory for Medical Engineering, Division of Materials and Chemical Engineering, Graduate School of Engineering, Yokohama National University, Kanagawa, Japan
                [5 ]Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan
                [6 ]Division of Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
                [7 ]NTT Medical Center Tokyo, Tokyo, Japan
                [8 ]Shionogi & Co., Ltd., Osaka, Japan
                [9 ]Institute of Predictive and Personalized Medicine of Cancer (IMPPC), Barcelona, Spain
                Kanazawa University, Japan
                Author notes

                Competing Interests: Hideki Ohta, Hiroyuki Okamoto and Hikaru Sonoda, are employees of Shionogi & Co., Ltd. Shionogi & Co., Ltd. has an exclusive license for several miRNAs presented in this work. Shionogi & Co., Ltd. has applied for a patent (WO2011/040525) for the development of these miRNAs as diagnostic markers. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

                Conceived and designed the experiments: NT. Performed the experiments: HOK MI DK H. Ohta H. Okamoto HS NT. Analyzed the data: HOK MI NT. Contributed reagents/materials/analysis tools: YH YY KF TG MW HN JY TK. Wrote the paper: HOK NT.

                Article
                PONE-D-13-47479
                10.1371/journal.pone.0092921
                3976275
                24705249
                42ef746c-d9c7-4d1a-89fd-8bce31cd247f
                Copyright @ 2014

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 13 November 2013
                : 26 February 2014
                Page count
                Pages: 9
                Funding
                Funding provided by The Advanced Research for Medical Products Mining Program of the National Institute of Biomedical Innovation (NIBIO)(08-02), http://www.nibio.go.jp; Grant-in-Aids from the Ministry of Health, Labor and Welfare (13802015), http://www.mhlw.go.jp/; Grant-in-Aids from the Ministry of Education, Culture, Sports & Technology of Japan (13314780), http://www.jsps.go.jp/; National Cancer Center Research and Development Fund (23-B-08), http://www.ncc.go.jp. National Cancer Center Biobank is supported by National Cancer Center Research and Development Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Biology and life sciences
                Biochemistry
                Biomarkers
                Nucleic Acids
                RNA
                Genetics
                Epigenetics
                RNA interference
                Gene Expression
                Medicine and Health Sciences
                Diagnostic Medicine
                Epidemiology
                Biomarker Epidemiology
                Oncology
                Cancers and Neoplasms
                Carcinomas
                Adenocarcinomas
                Colon Adenocarcinoma
                Gastrointestinal Tumors
                Cancer Detection and Diagnosis
                Cancer Risk Factors
                Pathology and Laboratory Medicine

                Uncategorized
                Uncategorized

                Comments

                Comment on this article